These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 34901990)
21. Intratracheal administration of budesonide with surfactant in very low birth weight infants to prevent bronchopulmonary dysplasia. Heo M; Jeon GW Turk J Pediatr; 2020; 62(4):551-559. PubMed ID: 32779407 [TBL] [Abstract][Full Text] [Related]
22. Noninvasive Ventilation and Exogenous Surfactant in Times of Ever Decreasing Gestational Age: How Do We Make the Most of These Tools? Wright CJ; Glaser K; Speer CP; Härtel C; Roehr CC J Pediatr; 2022 Aug; 247():138-146. PubMed ID: 35429507 [No Abstract] [Full Text] [Related]
23. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R; Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381 [TBL] [Abstract][Full Text] [Related]
24. Less invasive surfactant administration: best practices and unanswered questions. Herting E; Härtel C; Göpel W Curr Opin Pediatr; 2020 Apr; 32(2):228-234. PubMed ID: 32068592 [TBL] [Abstract][Full Text] [Related]
25. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia. Bassler D Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104 [TBL] [Abstract][Full Text] [Related]
26. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Soll RF; Morley CJ Cochrane Database Syst Rev; 2001; (2):CD000510. PubMed ID: 11405966 [TBL] [Abstract][Full Text] [Related]
27. Delivery room interventions to prevent bronchopulmonary dysplasia in extremely preterm infants. Foglia EE; Jensen EA; Kirpalani H J Perinatol; 2017 Nov; 37(11):1171-1179. PubMed ID: 28569744 [TBL] [Abstract][Full Text] [Related]
28. Less invasive surfactant administration: Will it change the outcome of preterm infants with respiratory distress syndrome? Jeng MJ J Chin Med Assoc; 2020 Aug; 83(8):699-700. PubMed ID: 32282450 [No Abstract] [Full Text] [Related]
29. Shaken or Stirred? Evaluating the combination of budesonide-surfactant for survival free of bronchopulmonary dysplasia. Willis K; Weems M Acta Paediatr; 2018 Mar; 107(3):540. PubMed ID: 29131394 [No Abstract] [Full Text] [Related]
30. Animal derived surfactant extract for treatment of respiratory distress syndrome. Seger N; Soll R Cochrane Database Syst Rev; 2009 Apr; (2):CD007836. PubMed ID: 19370695 [TBL] [Abstract][Full Text] [Related]
31. Prophylactic treatment of very premature infants with human surfactant. Merritt TA; Hallman M; Bloom BT; Berry C; Benirschke K; Sahn D; Key T; Edwards D; Jarvenpaa AL; Pohjavuori M N Engl J Med; 1986 Sep; 315(13):785-90. PubMed ID: 3528853 [TBL] [Abstract][Full Text] [Related]
32. Surfactant delivery via thin catheters: Methods, limitations, and outcomes. Devi U; Pandita A Pediatr Pulmonol; 2021 Oct; 56(10):3126-3141. PubMed ID: 34379878 [TBL] [Abstract][Full Text] [Related]
33. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Soll RF Cochrane Database Syst Rev; 2000; (2):CD001079. PubMed ID: 10796410 [TBL] [Abstract][Full Text] [Related]
34. [For or against the early use of nasal continuous positive pressure and exogenous surfactant in hyaline membrane disease. Physiopathologic arguments]. Storme L; Truffert P; Rakza T; Lequien P Arch Pediatr; 1999 May; 6(5):549-55. PubMed ID: 10370813 [TBL] [Abstract][Full Text] [Related]
35. Less invasive surfactant administration is associated with improved pulmonary outcomes in spontaneously breathing preterm infants. Göpel W; Kribs A; Härtel C; Avenarius S; Teig N; Groneck P; Olbertz D; Roll C; Vochem M; Weller U; von der Wense A; Wieg C; Wintgens J; Preuss M; Ziegler A; Roth B; Herting E; Acta Paediatr; 2015 Mar; 104(3):241-6. PubMed ID: 25474712 [TBL] [Abstract][Full Text] [Related]
36. Implementing less invasive surfactant administration on a neonatal unit. Williamson SL; McDermott H; Gowda H Arch Dis Child Educ Pract Ed; 2022 Aug; 107(4):298-301. PubMed ID: 33832959 [TBL] [Abstract][Full Text] [Related]
37. Late Surfactant Administration in Very Preterm Neonates With Prolonged Respiratory Distress and Pulmonary Outcome at 1 Year of Age: A Randomized Clinical Trial. Hascoët JM; Picaud JC; Ligi I; Blanc T; Moreau F; Pinturier MF; Zupan V; Guilhoto I; Hamon IR; Alexandre C; Bouissou A; Storme L; Patkai J; Pomedio M; Rouabah M; Coletto L; Vieux R JAMA Pediatr; 2016 Apr; 170(4):365-72. PubMed ID: 26928567 [TBL] [Abstract][Full Text] [Related]
38. Three-year perinatal outcomes of less invasive beractant administration in preterm infants with respiratory distress syndrome. Ramos-Navarro C; Sánchez-Luna M; Zeballos-Sarrato S; González-Pacheco N J Matern Fetal Neonatal Med; 2020 Aug; 33(16):2704-2710. PubMed ID: 30526187 [No Abstract] [Full Text] [Related]
39. Less invasive surfactant administration by umbilical catheter is safe and effective for treating respiratory distress syndrome in preterm infants. Truong TT; Tran HT; Skinner A; Narchi H Acta Paediatr; 2023 Apr; 112(4):706-707. PubMed ID: 36579363 [No Abstract] [Full Text] [Related]
40. Intratracheal Administration of Budesonide-Surfactant in Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants: A Systematic Review and Meta-Analysis. Venkataraman R; Kamaluddeen M; Hasan SU; Robertson HL; Lodha A Pediatr Pulmonol; 2017 Jul; 52(7):968-975. PubMed ID: 28165675 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]